S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease
Scope of application and rationale for the selected guideline topic
Despite a decreasing prevalence of infection with Helicobacter pylori (H. pylori) during the last decades, according to international population-based studies, about 50 % of the adult world population above the age of 40 years remains affected by this infection. There are no acknowledged prevention strategies. An effective vaccine is not available. Infection with H. pylori induces a chronic active gastritis. Possible complications or related diseases are dyspeptic symptoms, gastroduodenal ulcer disease, distal gastric cancer, primary gastric MALT (mucosa-associated lymphoid tissue) lymphoma, and extra-digestive diseases . H. pylori infection therefore has ongoing relevance, and due to new knowledge, we present an update and enhancement of the previous guideline from 2009 .
Aim of the guideline
Update of the guideline from 2009. New evidence concerning the definition, epidemiology, and resistance rates of H. pylori as well as progress in diagnosis and therapy will be assessed and integrated.
Patient target group
The guideline gives recommendations for adults who are suffering from H. pylori infection, related diseases, or from non-H. pyloriassociated gastroduodenal ulcer disease. Specific aspects of the infection in children will be discussed in a distinct chapter.
Area of care
The guideline is applicable for medical care in both the out- and the inpatient sector, addressing prevention, diagnostic approaches, and therapy for primary and specialist care.
User target group
All doctors involved in the consultation,
Helicobacter pylori, gastroduodenal ulcer disease, guideline
This item can be cited as: Z Gastroenterol 2017; 54: 167–206; PMID 27919112
You may be interested in:
English, Presentation, European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), 2015
- Standards and Guidelines
UEG Week Pathway
- Stomach & H. Pylori